<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4DC5FE59-469D-4D4C-B472-4A033176D6BB"><gtr:id>4DC5FE59-469D-4D4C-B472-4A033176D6BB</gtr:id><gtr:name>Sirakoss Limited</gtr:name><gtr:address><gtr:line1>5TH FLOOR , 125 PRINCES STREET</gtr:line1><gtr:city>EDINBURGH</gtr:city><gtr:postCode>EH2 4AD</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4DC5FE59-469D-4D4C-B472-4A033176D6BB" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>4DC5FE59-469D-4D4C-B472-4A033176D6BB</gtr:id><gtr:name>Sirakoss Limited</gtr:name><gtr:address><gtr:line1>5TH FLOOR , 125 PRINCES STREET</gtr:line1><gtr:city>EDINBURGH</gtr:city><gtr:postCode>EH2 4AD</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>939895.0</gtr:offerGrant><gtr:projectCost>1566492.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/BE65A239-4B5A-4845-867D-026E93EE0922"><gtr:id>BE65A239-4B5A-4845-867D-026E93EE0922</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:surname>Butchart</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=102011"><gtr:id>CC889985-6D44-4780-9955-236C956CCA38</gtr:id><gtr:title>Production and pre-clinical testing of MaxSi? Graft synthetic bone graft substitutes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>102011</gtr:grantReference><gtr:abstractText>SIRAKOSS Ltd have developed a novel bone graft substitute (BGS) that will revolutionise the treatment of bone defects and fusions. Developed to offer the surgeon an alternative to having to graft the patient?s own bone, which involves a second surgical procedure associated with graft site pain and increased healthcare costs, the SIRAKOSS synthetic implants are capable of regenerating bone in fractures and bone defects. Bone is the second most commonly transplanted tissue, next to blood, with over 2 million bone graft procedures performed worldwide every year. Biomedical Catalyst funding of &amp;pound;900,000 will allow SIRAKOSS to finalise development of their novel bone graft substitute and complete pre-clinical testing to support regulatory approval for clinical use in Europe.</gtr:abstractText><gtr:fund><gtr:end>2017-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>939895</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">102011</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>